Journal of Pharmacy Technology最新文献_第9页

Decline and Pronounced Regional Disparities in Medical Cocaine Usage in the United States. 美国医疗可卡因使用量的下降和明显的地区差异。

IF 1

Journal of Pharmacy Technology Pub Date : 2021-12-01 Epub Date: 2021-07-30 DOI: 10.1177/87551225211035563

Youngeun C Armbuster, Brian N Banas, Kristen D Feickert, Stephanie E England, Erik J Moyer, Emily L Christie, Sana Chughtai, Tanya J Giuliani, Rolf U Halden, Jove H Graham, Kenneth L McCall, Brian J Piper

{"title":"Decline and Pronounced Regional Disparities in Medical Cocaine Usage in the United States.","authors":"Youngeun C Armbuster, Brian N Banas, Kristen D Feickert, Stephanie E England, Erik J Moyer, Emily L Christie, Sana Chughtai, Tanya J Giuliani, Rolf U Halden, Jove H Graham, Kenneth L McCall, Brian J Piper","doi":"10.1177/87551225211035563","DOIUrl":"https://doi.org/10.1177/87551225211035563","url":null,"abstract":"Background: Cocaine is a stimulant and Schedule II drug used as a local anesthetic and vasoconstrictor. Objective: This descriptive study characterized medical cocaine use in the United States. Methods: Retail drug distribution data from 2002 to 2017 were extracted for each state from the Drug Enforcement Administration, which reports on medical, research, and analytical chemistry use. The percentage of buyers (pharmacies, hospitals, and providers) was obtained. Use per state, corrected for population, was determined. Available cross-sectional data on cocaine use as reported by the Medicare and Medicaid programs for 2013-2017 and electronic medical records were examined. Results: Medical cocaine use decreased by -62.5% from 2002 to 2017. Hospitals accounted for 84.9% and practitioners for 9.9% of cocaine distribution in 2017. The number of pharmacies carrying cocaine dropped by -69.4%. The percentages of hospitals, practitioners, and pharmacies that carried cocaine in 2017 were 38.4%, 2.3%, and 0.3%, respectively. There was a 7-fold difference in 2002 (South Dakota, 76.1 mg/100 persons; Delaware, 10.1 mg/100 persons). Relative to the average state in 2017, those reporting the highest values (Montana, 20.1; North Dakota, 24.1 mg/100 persons) were significantly elevated. Cocaine use within the Medicare and Medicaid programs was negligible. Cocaine use within the Geisinger system was rare from 2002 to 2007 (<4 orders/100 000 patients per year) but increased to 48.7 in 2018. Conclusion and Relevance: If these pharmacoepidemiological patterns continue, licit cocaine may soon become a historical relic. The pharmacology and pharmacotherapeutics education of health care providers may need to be adjusted accordingly.","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":"37 6","pages":"278-285"},"PeriodicalIF":1.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/87551225211035563","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39633878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Evaluation of an Initiation Regimen of Warfarin for International Normalized Ratio Target 2.0 to 3.0. 华法林起始治疗方案对国际标准化比值目标2.0 ~ 3.0的评价。

IF 1

Journal of Pharmacy Technology Pub Date : 2021-12-01 Epub Date: 2021-08-05 DOI: 10.1177/87551225211034175

Sahimi Mohamed, Chan Mei Fong, Yew Jie Ming, Ahlam Naila Kori, Sopian Abdul Wahab, Zarina Mohd Ali

{"title":"Evaluation of an Initiation Regimen of Warfarin for International Normalized Ratio Target 2.0 to 3.0.","authors":"Sahimi Mohamed, Chan Mei Fong, Yew Jie Ming, Ahlam Naila Kori, Sopian Abdul Wahab, Zarina Mohd Ali","doi":"10.1177/87551225211034175","DOIUrl":"https://doi.org/10.1177/87551225211034175","url":null,"abstract":"Background: he number of patients on warfarin therapy is rising steadily. Although warfarin is beneficial, it carries a high risk of bleeding, especially if the international normalized ratio (INR) values exceed 3.0. Currently, no warfarin initiation regimens have been developed for the Asian population, especially for Malaysians. Objective: This article describes the efficacy and safety of a new initiation regimen for warfarin among warfarin-naive patients. Method: Data were retrospectively collected from the ambulatory and inpatient settings. Results: A total of 165 patients who each had a target INR of 2.0 to 3.0 were included in the study. The mean age was 57.2 years and 94 patients were male. A total of 108 patients used Regimen 1 (5 mg/5 mg/3mg) and the rest of the patients used Regimen 2 (5 mg/3 mg/3 mg). Most patients used warfarin either for atrial fibrillation (52.1%) or for venous thromboembolism (29.7%). Overall, 88 of the patients had INR values above 50% from the baseline on Day 4. Additionally, 13 patients had INR values of >3.2, which required withholding and lower dose of warfarin. The predicted weekly maintenance warfarin dose (23 ± 0.5 mg/week) was found to have correlated closely with the actual maintenance dose (22.8 ± 0.5 mg/week; r 2 = 0.75). Nearly two thirds (70.3%) of the patients achieved the target INR on Day 11. Conclusion: The warfarin initiation regimens in this study was simple, safe, and suitable to be used in both ambulatory and inpatient settings for managing warfarin therapy.","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":"37 6","pages":"286-292"},"PeriodicalIF":1.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8592241/pdf/10.1177_87551225211034175.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39633879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Retention of Sterile Compounding Knowledge Among Pharmacy Technicians. 药学技术人员对无菌配药知识的保留。

IF 1

Journal of Pharmacy Technology Pub Date : 2021-10-01 Epub Date: 2021-07-20 DOI: 10.1177/87551225211032395

Jameda Davis, Candace Ayars

{"title":"Retention of Sterile Compounding Knowledge Among Pharmacy Technicians.","authors":"Jameda Davis, Candace Ayars","doi":"10.1177/87551225211032395","DOIUrl":"https://doi.org/10.1177/87551225211032395","url":null,"abstract":"Background: Patient safety is in jeopardy due to a rise in the preparation of adulterated parenteral products with poor technique identified as a significant contributing factor. Pharmacy technicians perform an overwhelming majority of aseptic compounding practices; however, this group's progressive loss of aseptic technique knowledge has not been documented. Objective: The purpose of this correlational research study was to investigate the association between sterile compounding knowledge and years in the field controlling for formal training in sterile compounding techniques. Methods: An assessment tool of fundamental sterile compounding content was electronically distributed to sterile compounding technician members of pharmacy organizations in the southeastern United States. A multiple regression was conducted to predict sterile compounding knowledge from number of years in the field and prior years of formal compounding training. Results: Sixty-eight assessments were returned complete. The overall model was significant (P < .0005), explaining 22% of the variance in knowledge retention. Years in the field was the only significant predictor (P < .001). Each additional year of work experience was associated with a 0.18 drop in the assessment score. Conclusions: The longer pharmacy technicians remain in the field, the more aseptic technique knowledge they will lose. Modeling of poor sterile compounding techniques in the workplace may promote loss of competency of the skill. As a result, a plan to address continuing education for pharmacy technician sterile compounders is necessary to ensure patient safety.","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":"37 5","pages":"219-224"},"PeriodicalIF":1.0,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/87551225211032395","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39710345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Impact of Protocolized Pharmacist Intervention on Critical Activated Partial Thromboplastin Time Values With Heparin Infusions. 方案化药师干预对肝素输注临界活化部分凝血活酶时间值的影响。

IF 1

Journal of Pharmacy Technology Pub Date : 2021-10-01 Epub Date: 2021-07-14 DOI: 10.1177/87551225211031923

Rachelle Barry, Craig A Stevens, Trina Huynh, Dmitri Lerner

{"title":"Impact of Protocolized Pharmacist Intervention on Critical Activated Partial Thromboplastin Time Values With Heparin Infusions.","authors":"Rachelle Barry, Craig A Stevens, Trina Huynh, Dmitri Lerner","doi":"10.1177/87551225211031923","DOIUrl":"https://doi.org/10.1177/87551225211031923","url":null,"abstract":"Background: Unfractionated heparin (UFH) infusions are commonly managed with nurse-driven nomograms titrated to activated partial thromboplastin time (aPTT). In some patients, anti-Xa values may be more appropriate measures of anticoagulation. At the present institution, an update to the nurse-driven aPTT nomogram requires pharmacist notification and clinical assessment for critically supratherapeutic aPTT results. Objective: The purpose of this study was to evaluate the efficacy and safety of the nomogram update. Methods: A single-center, retrospective, pre-post analysis was conducted in patients treated with UFH who experienced a critical aPTT during the 6 months preceding and following the nomogram update. Patients with erroneous critical aPTT results were excluded. The primary endpoint was the time in therapeutic range (Rosendaal method) from the first critical aPTT until UFH discontinuation. Secondary endpoints included the proportion of patients transitioned to anti-Xa monitoring and the incidence of Bleeding Academic Research Consortium (BARC) 2, 3, 5 bleeding. Data were analyzed by the χ2 test. The study was institutional review board approved. Results: Of 277 UFH infusions, 142 belonged to the pre-implementation group and 135 to the post-implementation group. Baseline aPTTs were similar between the 2 groups. Time in therapeutic range was 58.1% versus 62.4% of between groups (P = .467). UFH was transitioned to pharmacist-driven anti-Xa monitoring in 16.2% versus 40.3% of patients (P < .001). BARC 2, 3, 5 bleeding occurred in 23.2% versus 13.4% of patients (P < .001). Conclusions: Application of these data suggest improved safety and efficacy outcomes with directed pharmacist management of UFH in patients with critically elevated aPTTs.","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":"37 5","pages":"225-233"},"PeriodicalIF":1.0,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/87551225211031923","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39709896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lasmiditan: Acute Migraine Treatment Without Vasoconstriction. A Review. 拉斯米坦:无血管收缩的急性偏头痛治疗。复习一下。

IF 1

Journal of Pharmacy Technology Pub Date : 2021-10-01 Epub Date: 2021-06-21 DOI: 10.1177/87551225211024630

Juliana K Beauchene, Terri L Levien

{"title":"Lasmiditan: Acute Migraine Treatment Without Vasoconstriction. A Review.","authors":"Juliana K Beauchene, Terri L Levien","doi":"10.1177/87551225211024630","DOIUrl":"https://doi.org/10.1177/87551225211024630","url":null,"abstract":"Objective: To review the efficacy and safety of the newly Food and Drug Administration approved drug lasmiditan, and its place in therapy in the treatment of acute migraine attacks. Data Sources: A literature search of Web of Science, PubMed, and Google Scholar was preformed (September 1999 to May 2021) using the following search terms: acute migraine treatment, triptans, lasmiditan, Reyvow, Rimegepant, Nurtec, Ubrogepant, Ubrelvy, migraine, vasoconstriction, and cardiovascular risk. Product labeling, https://www.clinicaltriasl.gov, and product monographs were also reviewed. Study Selection and Data Extraction: Relevant English-language studies were considered. Data Synthesis: Lasmiditan is the first in its class approved for acute migraine treatment. Lasmiditan exerts its therapeutic effect through agonism at the 5-HT1F receptor, which has been shown to produce no vasoconstriction in preclinical models. Relevance to Patient Care and Clinical Practice: It is both scientifically and clinically relevant to review lasmiditan and determine the value of an acute migraine drug that does not induce vasoconstriction. Patients with preexisting cardiovascular conditions for which current migraine therapy is contraindicated may benefit from therapeutic use of lasmiditan. However, the potential cardiovascular benefit needs to be weighed against the increased central nervous system risks observed with lasmiditan. Conclusions: Lasmiditan is an oral tablet drug that is used for acute migraine abortive treatment and data suggest that it does not induce vasoconstriction, a common side effect often observed with the current first-line abortive migraine treatment drug class, triptans. This is especially important in acute migraine patients with cardiovascular risk factors in which triptan use is contraindicated.","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":"37 5","pages":"244-253"},"PeriodicalIF":1.0,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/87551225211024630","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39603322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

A Systematic Review on KAP of Nebulization Therapy at Home. 家庭雾化治疗KAP的系统综述。

IF 1

Journal of Pharmacy Technology Pub Date : 2021-10-01 Epub Date: 2021-07-11 DOI: 10.1177/87551225211031331

Shalini Sivadasan, Akshaya Krishnan, Sathish Venkatasamy Dhayalan, Rajasekaran Aiyalu

{"title":"A Systematic Review on KAP of Nebulization Therapy at Home.","authors":"Shalini Sivadasan, Akshaya Krishnan, Sathish Venkatasamy Dhayalan, Rajasekaran Aiyalu","doi":"10.1177/87551225211031331","DOIUrl":"https://doi.org/10.1177/87551225211031331","url":null,"abstract":"Background: Inhalation is the preferred method of delivering medication for respiratory conditions such as asthma, chronic obstructive pulmonary disease, and other respiratory disease. A nebulizer converts a medication in liquid form to mist, so that the medication can be inhaled into the lungs. The aim of the study is to systematically review the knowledge, attitude, and practice of patients using nebulization therapy at home. The objective of the study is to review the procedure of nebulizer technique and to interpret the outcome of the studies. Method: Scopus, PubMed, BMJ, and other database from 2000 to 2020 were searched using Boolean operators. Title and abstract were screened for nebulizer technology and for inclusion and exclusion criteria. After full text screening 16 articles were included in the study. Result: Use of nebulizer at home was a challenge at all stages including setting up and operating nebulizer, filling up of medication, inhalation technique, end point dismantling, and maintenance. The main challenge experienced by the participants was with cleaning and disinfecting of nebulizer. There were studies that reported with 71.6% pathogen contamination due to inappropriate cleaning and disinfecting. Conclusion: Patients with respiratory disease using nebulizers at home find difficulty in appropriate and rational use of the device. Apart from the nebulizer user guidelines from the manufactures, it is suggested that a short audio visual demonstrating the appropriate and effective use of nebulizers and also its maintenance in their colloquial language with handout infographics would highly facilitate the effective use of nebulizers.","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":"37 5","pages":"254-259"},"PeriodicalIF":1.0,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/87551225211031331","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39603323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Development of an Emergency Revisit Score for Patients With Drug-Related Problems. 药物相关问题患者紧急重访评分的发展

IF 1

Journal of Pharmacy Technology Pub Date : 2021-08-01 Epub Date: 2021-04-30 DOI: 10.1177/87551225211011731

Jesus Ruiz Ramos, Laura Gras-Martin, Ana María Juanes Borrego, Marta Blazquez-Andion, Mireia Puig Campmany, Maria Antonia Mangues-Bafalluy

{"title":"Development of an Emergency Revisit Score for Patients With Drug-Related Problems.","authors":"Jesus Ruiz Ramos, Laura Gras-Martin, Ana María Juanes Borrego, Marta Blazquez-Andion, Mireia Puig Campmany, Maria Antonia Mangues-Bafalluy","doi":"10.1177/87551225211011731","DOIUrl":"https://doi.org/10.1177/87551225211011731","url":null,"abstract":"Background: Drug-related problems (DRPs) are a frequent reason for emergency departments (EDs) visits. However, data about the risk factors associated with EDs revisits are limited. Objective: To develop and validate a predictive model indicating the risk factors associated with EDs revisit within 30 days of the first visit. Methods: A retrospective cohort study was conducted involving patients who attended an ED for DRPs related to cardiovascular drugs. A 30-day prediction model was created in a derivation cohort by logistic regression. An integer score proportional to the regression coefficient was assigned to the variables with P < .100 in the multivariate analysis. Results: 581 patients (mean age: 80.0 [12.6] years) were included, 133 (22.9%) revisited the ED within 30 days from discharge. Six factors (chronic kidney disease, chronic heart failure, visit to an ED in the preceding 3 months, high anticholinergic burden, DRPs associated with heparin, and safety-related DRPs) were identified as risk factors and combined into a final score, termed the DREAMER score. The model reached an area under the receiver operating curve values of 0.72 (95% confidence interval [CI] = 0.67-0.77) in the referral cohort and 0.71 (95% CI = 0.65-0.74) in the validation cohort (P = .273). Three risk categories were generated, with the following scores and estimated risks: low risk (0-8 points): 11.6%; intermediate risk (9-14 points): 21.3%; and high risk (>14 points): 41.2%. Conclusion and Relevance: The DREAMER score identifies patients at high risk for ED revisit within 30 days from the first visit for a DRPs, being a useful tool to prioritize interventions on discharge.","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":"37 4","pages":"171-177"},"PeriodicalIF":1.0,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/87551225211011731","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39603309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Safety and Efficacy of Apixaban Following Bioprosthetic Valve Replacements: A Retrospective Evaluation. 阿哌沙班在生物瓣膜置换术后的安全性和有效性:回顾性评价。

IF 1

Journal of Pharmacy Technology Pub Date : 2021-08-01 Epub Date: 2021-06-04 DOI: 10.1177/87551225211021596

Kellie Ball, Elizabeth W Covington

{"title":"Safety and Efficacy of Apixaban Following Bioprosthetic Valve Replacements: A Retrospective Evaluation.","authors":"Kellie Ball, Elizabeth W Covington","doi":"10.1177/87551225211021596","DOIUrl":"https://doi.org/10.1177/87551225211021596","url":null,"abstract":"Background: Data on the use of direct oral anticoagulants in the setting of bioprosthetic valve replacements is limited. Objective: The purpose of this study was to describe outcomes among patients who underwent a bioprosthetic valve replacement and were subsequently prescribed apixaban. Methods: A retrospective cohort study was completed for inpatients at a community hospital who were prescribed apixaban following a bioprosthetic valve replacement from 2015 to 2020. Endpoints assessed included incidence of all-cause readmission and emergency visits within 3 months following valvular surgery, incidence of mortality, and all-cause major and minor bleeding. A post hoc analysis was conducted comparing outcomes among patients who underwent mitral versus aortic valve replacement, as well as patients with and without atrial fibrillation. The study was deemed exempt by hospital and university institutional review boards. Results: A total of 54 patients were included for analysis. All-cause readmission or emergency visit occurred in 33% (n = 18) of patients and the mortality rate was 6% (n = 3). A minor bleeding event was reported in 6% (n = 3) of patients and a major bleeding event was reported in 2% (n = 1) of patients. A thrombotic event was reported in 2% (n = 1) of patients. Conclusion: Within this cohort of patients requiring anticoagulation following bioprosthetic valve replacement, apixaban was safe and well-tolerated. However, more prospective data are needed to further correlate the safety and efficacy of apixaban, particularly in the setting of mitral valve replacement.","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":"37 4","pages":"193-201"},"PeriodicalIF":1.0,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/87551225211021596","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39602955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Crizanlizumab for the Prevention of Vaso-Occlusive Pain Crises in Sickle Cell Disease. criszanlizumab用于预防镰状细胞病血管闭塞性疼痛危机。

IF 1

Journal of Pharmacy Technology Pub Date : 2021-08-01 Epub Date: 2021-04-19 DOI: 10.1177/87551225211008460

Debra L Stevens, Meri Hix, Brooke L Gildon

{"title":"Crizanlizumab for the Prevention of Vaso-Occlusive Pain Crises in Sickle Cell Disease.","authors":"Debra L Stevens, Meri Hix, Brooke L Gildon","doi":"10.1177/87551225211008460","DOIUrl":"https://doi.org/10.1177/87551225211008460","url":null,"abstract":"Objective: To review the efficacy and safety of crizanlizumab (Adakveo) in the prevention of vaso-occlusive pain crises in sickle cell disease. Data Sources: An English-language literature search of PubMed, MEDLINE, and Ovid (1946 to January 2021) was completed using the terms crizanlizumab, SEG101, SelG1, and sickle cell disease. Manufacturer prescribing information, article bibliographies, and data from clinicaltrials.gov were incorporated in the reviewed data. Study Selection/Data Extraction: All studies registered on clinicaltrials.gov were incorporated in the reviewed data. Data Synthesis: Crizanlizumab is the first monoclonal antibody approved for sickle cell disease to reduce the frequency of vaso-occlusive crises. One phase 2 clinical trial and a post hoc analysis of the trial have been published. Relevance to Patient Care and Clinical Practice: Crizanlizumab is a monthly intravenous infusion approved by the Food and Drug Administration for patients with sickle cell disease 16 years of age and older to reduce the frequency of vaso-occlusive crises. Conclusion: Crizanlizumab appears to be an efficacious therapy for patients with sickle cell disease to reduce the frequency of vaso-occlusive crises. Concerns include drug cost and administration. Long-term benefits and risks have not been determined.","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":"37 4","pages":"209-215"},"PeriodicalIF":1.0,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/87551225211008460","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39603313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Efficacy and Safety Considerations With Second-Generation Antipsychotics as Adjunctive Analgesics: A Review of Literature. 第二代抗精神病药作为辅助镇痛药的疗效和安全性:文献综述。

IF 1

Journal of Pharmacy Technology Pub Date : 2021-08-01 Epub Date: 2021-04-19 DOI: 10.1177/87551225211004145

Belinda Coronado, Jacob Dunn, Michael A Veronin, Justin P Reinert

{"title":"Efficacy and Safety Considerations With Second-Generation Antipsychotics as Adjunctive Analgesics: A Review of Literature.","authors":"Belinda Coronado, Jacob Dunn, Michael A Veronin, Justin P Reinert","doi":"10.1177/87551225211004145","DOIUrl":"https://doi.org/10.1177/87551225211004145","url":null,"abstract":"Objective: To determine the efficacy and safety of second-generation antipsychotics (SGAs) as adjunctive analgesics. Data Sources: A comprehensive literature review was conducted between August 2020 and January 2021 on PubMed, Scopus, and ProQuest Central. Study Selection and Data Extraction: Keyword and Boolean phrase searches using the following terminology were conducted: \"Quetiapine\" OR \"Risperidone\" OR \"Olanzapine\" OR \"Ziprasidone\" AND \"Analgesia\" NOT \"Psychosis\" NOT \"Psych.\" Articles that involved human adult patients who received any of the SGAs mentioned in the searching filter with an opioid were included. Articles that described pediatrics, pregnant women, patients who received any of these agents for treatment of psychosis and articles that were not in English, or readily translatable to English, were excluded. Data Synthesis: Three articles were selected for inclusion in this review, with 2 articles detailing reports with olanzapine and 1 article describing a randomized, controlled trial with extended-release quetiapine. Both olanzapine and quetiapine were able to decrease pain scores on the numeric rating scale, indicating a reduction pain experienced, and additionally reduced opioid craving behavior in patients. Depression scores and quality-of-life indicators improved with quetiapine, though those metrics were not studied with olanzapine. Conclusions: Select SGAs, specifically extended-release quetiapine and olanzapine, may serve as an appropriate adjunctive analgesic choice in select patients. Further research is required in a clinical setting to determine the exact role of this drug class in pain management.","PeriodicalId":16796,"journal":{"name":"Journal of Pharmacy Technology","volume":"37 4","pages":"202-208"},"PeriodicalIF":1.0,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/87551225211004145","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39603311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1